Critical Therapeutics kept at market outperform by JMP

Critical Therapeutics, Inc. was reiterated at market outperform by JMP Securities analyst Adam Cutler. The company reported a loss per share of $0.49 compared with JMP's estimate of $0.53 and Street consensus of $0.47. Revenues were $2.3 million versus the analyst's estimate of $2.2 million and consensus of $2.6 million. Shares of the Lexington, Mass., biopharmaceutical company were down 53 cents, or 10.56%, at $4.45 on volume of 637,405 shares versus the three-month running average of 105,135 shares. (Nasdaq: CRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.